Learn how early regulatory engagement, validated digital systems, and robust protocol design enable biotechs to run parallel ...
At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...
At ESMO 2025, Eli Lilly’s Verzenio and Novartis’ Kisqali both demonstrated durable efficacy in hormone receptor-positive, ...
In this week’s Applied Clinical Trials Brief, we highlight key findings from the 2025 State of the Industry Survey, explore how AI is transforming trial efficiency and patient engagement, and examine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback